Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

Table 4 Adverse effect counts, n (%)

Groups	Hypoglycemic reaction	Urinary tract infection	Gastrointestinal adverse effect	Respiratory distress	Vascular edema
Control group (n = 51)	3 (5.88)	2 (3.92)	3 (5.88)	1 (1.96)	2 (3.92)
Study group (n = 51)	2 (3.92)	1 (1.96)	1 (1.96)	2 (3.92)	3 (5.88)
χ2	0.210	0.343	1.041	0.343	0.210
P value	0.647	0.558	0.307	0.558	0.647